Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET
Company Participants
Robert Barrow - Chief Executive Officer
Schond Greenway - Chief Financial Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Elemer Piros - ROTH Capital Partners
Patrick Trucchio - H.C. Wainwright
Sepehr Manochehry - Eight Capital
Operator
Good afternoon and welcome to the Mind Medicine Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded.
It is now my pleasure to introduce your host Robert Barrow, Chief Executive Officer and Director at Mind Medicine. Mr. Barrow, you may begin your conference.
Robert Barrow
Thank you, operator and good afternoon everyone. Welcome to MindMed second quarter 2022 financial results and corporate update conference call. Following market close, we issued a press release with the summary of our results.
The press release reporting our financial results is available in the Investors and Media section of MindMed’s website and our quarterly report on Form 10-Q for the quarter ended June 30, 2022 will be filed today with the Securities and Exchange Commission.
Joining me on today’s call is Schond Greenway, our Chief Financial Officer, Dr. Miri Halperin Wernli, our Executive President and Dr. Daniel Karlin, our Chief Medical Officer. During the course of today’s, I will provide an overview and update on our business and Schond will review financial results for the quarter ended June 30, 2022 followed by Q&A.
For I began, let me remind you that during this conference call, we will be making Forward-Looking Statements. Company’s actual results may differ materially from those expressed and/or indicated by such Forward-Looking Statements. For description of risks, please refer to our quarterly and annual filings with the Securities and Exchange Commission.
Today, I will begin with an update on our corporate strategy. During the course of the quarter, we undertook a review of all of our assets, R&D programs and our overall business strategy. Based on this assessment, we were reaffirming our key near-term strategic priorities and are focusing our resources on advancing our MM-120 program in Psychiatric Education, specifically Generalized Anxiety Disorder and Attention Deficit Hyperactivity Disorder and our MM-402 program and Autism Spectrum Disorder.
We believe the enhanced focus of resources on these programs represents a cost effective approach to advancing the programs in are pipeline that have the highest probability to generate near-term value for our shareholders. We reflect spectrum MM-110 development program, which is a non-hallucinogenic congener of ibogaine.